Zilucoplan (RA101495; 10 mg/kg; S.C.; daily, for 6 d) prevents the development of immune-mediated necrotising myopathy (IMNM) in C5-deficient mice supplemented with human complement[1].
Zilucoplan (10 mg/kg; S.C.; daily, for 6 d) has protection on myopathy prevention in C57BL/6 mice[1].
| Animal Model: | C57BL/10SnJ C5-deficient (C5def) mice with anti-HMGCR+ IMNM IgG xenografts[1] |
| Dosage: | 10 mg/kg |
| Administration: | Subcutaneous injection; daily, for 6 days |
| Result: | Prevented muscle strength loss in C5def mice with less complement deposition on myofibres and consequently less necrosis/regeneration. |
| Animal Model: | C57BL/6 mice with anti-HMGCR+ IMNM IgG xenografts[1] |
| Dosage: | 10 mg/kg |
| Administration: | Subcutaneous injection; daily, for 6 days |
| Result: | Prevented muscle weakness and reduced regenerated myofibres.
Decreased necrotic cells as well as regenerating cells expressing foetal myosin.
|
